MaxCyte (MXCT) announced the signing of a strategic partnership with Prime Medicine (PRME). Under the terms of the agreement, Prime Medicine obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive annual license fees and program-related revenue. “We are pleased to partner with Prime Medicine and support their breakthrough gene editing technology,” said Doug Doerfler, President and CEO of MaxCyte. “The company’s innovative vision and transformative scientific approach are clearly reshaping how genetic diseases are studied and ultimately will be treated.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MXCT:
- MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
- MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
- MaxCyte, Vittoria Biotherapeutics sign strategic platform license
- MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
- MaxCyte signs strategic platform license with Lyell Immunopharma